Hemozoin As a Novel Adjuvant for Inactivated Whole Virion Influenza Vaccine

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2014 Aug 10

PMID 25108216

Citations 8

Authors

Ryuta Uraki

Subash C Das

Masato Hatta

Maki Kiso

Kiyoko Iwatsuki-Horimoto

Makoto Ozawa

Cevayir Coban

Ken J Ishii

Yoshihiro Kawaoka

Affiliations

Soon will be listed here.

Abstract

Because vaccination is an effective means to protect humans from influenza viruses, extensive efforts have been made to develop not only new vaccines, but also for new adjuvants to enhance the efficacy of existing inactivated vaccines. Here, we examined the adjuvanticity of synthetic hemozoin, a synthetic version of the malarial by-product hemozoin, on the vaccine efficacy of inactivated whole influenza viruses in a mouse model. We found that mice immunized twice with hemozoin-adjuvanted inactivated A/California/04/2009 (H1N1pdm09) or A/Vietnam/1203/2004 (H5N1) virus elicited higher virus-specific antibody responses than did mice immunized with non-adjuvanted counterparts. Furthermore, mice immunized with hemozoin-adjuvanted inactivated viruses were better protected from lethal challenge with influenza viruses than were mice immunized with non-adjuvanted inactivated vaccines. Our results show that hemozoin improves the immunogenicity of inactivated influenza viruses, and is thus a promising adjuvant for inactivated whole virion influenza vaccines.

Citing Articles

Plasmodium berghei Purified Hemozoin Associated with DNA Strongly Inhibits P. berghei Liver-Stage Development in BALB/c Mice after Intravenous Inoculation.

Franco A, Flores-Garcia Y, Zavala F, Sullivan D Infect Immun. 2023; 91(1):e0030422.

PMID: 36622216 PMC: 9872621. DOI: 10.1128/iai.00304-22.

A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine.

Feng H, Sun R, Song G, Zhu S, Nie Z, Lin L Viruses. 2022; 14(6).

PMID: 35746644 PMC: 9230830. DOI: 10.3390/v14061174.

Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine.

Feng H, Nakatsu S, da Silva Lopes T, Imai M, Yamayoshi S, Yamashita M Vaccines (Basel). 2020; 8(2).

PMID: 32397625 PMC: 7349346. DOI: 10.3390/vaccines8020215.

A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice.

Feng H, Nakajima N, Wu L, Yamashita M, Lopes T, Tsuji M Front Microbiol. 2019; 10:2157.

PMID: 31620111 PMC: 6759631. DOI: 10.3389/fmicb.2019.02157.

Food Additives as Novel Influenza Vaccine Adjuvants.

Feng H, Yamashita M, Wu L, da Silva Lopes T, Watanabe T, Kawaoka Y Vaccines (Basel). 2019; 7(4).

PMID: 31554190 PMC: 6963695. DOI: 10.3390/vaccines7040127.

References

Coban C, Ishii K, Kawai T, Hemmi H, Sato S, Uematsu S . Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med. 2005; 201(1):19-25. PMC: 2212757. DOI: 10.1084/jem.20041836. View

Rimmelzwaan G, Fouchier R, Osterhaus A . Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol. 2007; 18(6):529-36. DOI: 10.1016/j.copbio.2007.11.002. View

Parroche P, Lauw F, Goutagny N, Latz E, Monks B, Visintin A . Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci U S A. 2007; 104(6):1919-24. PMC: 1794278. DOI: 10.1073/pnas.0608745104. View

Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y . Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res. 2011; 158(1-2):124-9. PMC: 3103651. DOI: 10.1016/j.virusres.2011.03.022. View

Benton K, Misplon J, Lo C, Brutkiewicz R, Prasad S, Epstein S . Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J Immunol. 2001; 166(12):7437-45. DOI: 10.4049/jimmunol.166.12.7437. View

Clements M, Betts R, Tierney E, Murphy B . Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986; 24(1):157-60. PMC: 268857. DOI: 10.1128/jcm.24.1.157-160.1986. View

Kida H, Brown L, Webster R . Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology. 1982; 122(1):38-47. DOI: 10.1016/0042-6822(82)90375-0. View

Nabel G, Fauci A . Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med. 2010; 16(12):1389-91. DOI: 10.1038/nm1210-1389. View

Glezen W . Cold-adapted, live attenuated influenza vaccine. Expert Rev Vaccines. 2004; 3(2):131-9. DOI: 10.1586/14760584.3.2.131. View

10.

Cox R, Brokstad K, Zuckerman M, Wood J, Haaheim L, Oxford J . An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine. 1994; 12(11):993-9. DOI: 10.1016/0264-410x(94)90334-4. View

11.

Petrovsky N, Aguilar J . Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004; 82(5):488-96. DOI: 10.1111/j.0818-9641.2004.01272.x. View

12.

Reed S, Orr M, Fox C . Key roles of adjuvants in modern vaccines. Nat Med. 2013; 19(12):1597-608. DOI: 10.1038/nm.3409. View

13.

Coban C, Igari Y, Yagi M, Reimer T, Koyama S, Aoshi T . Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe. 2010; 7(1):50-61. DOI: 10.1016/j.chom.2009.12.003. View

14.

Onishi M, Kitano M, Taniguchi K, Homma T, Kobayashi M, Sato A . Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets. Vaccine. 2014; 32(25):3004-9. DOI: 10.1016/j.vaccine.2014.03.072. View

15.

van Riet E, Ainai A, Suzuki T, Hasegawa H . Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine. 2012; 30(40):5893-900. DOI: 10.1016/j.vaccine.2012.04.109. View

16.

Das S, Hatta M, Wilker P, Myc A, Hamouda T, Neumann G . Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine. 2012; 30(48):6871-7. PMC: 3488283. DOI: 10.1016/j.vaccine.2012.09.007. View

17.

Yamada S, Hatta M, Staker B, Watanabe S, Imai M, Shinya K . Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathog. 2010; 6(8):e1001034. PMC: 2916879. DOI: 10.1371/journal.ppat.1001034. View

18.

Shio M, Kassa F, Bellemare M, Olivier M . Innate inflammatory response to the malarial pigment hemozoin. Microbes Infect. 2010; 12(12-13):889-99. DOI: 10.1016/j.micinf.2010.07.001. View

19.

Dey A, Srivastava I . Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert Rev Vaccines. 2010; 10(2):227-51. DOI: 10.1586/erv.10.142. View

20.

Lambert L, Fauci A . Influenza vaccines for the future. N Engl J Med. 2010; 363(21):2036-44. DOI: 10.1056/NEJMra1002842. View